|
Nov 15
|
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA
|
|
Nov 8
|
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Ascendis Pharma Reports Third Quarter 2023 Financial Results
|
|
Apr 27
|
Ascendis Pharma Reports First Quarter 2023 Financial Results
|
|
Apr 22
|
An Intrinsic Calculation For Ascendis Pharma A/S (NASDAQ:ASND) Suggests It's 20% Undervalued
|